Why the study?
The study was conducted to evaluate the effects of Sacubitril/Valsartan on clinical, laboratory, and echocardiographic parameters and outcomes in a real-world HFrEF population.
Does Sacubitril/Valsartan reduce the composite of cardiac death and HF rehospitalization in patients with HFrEF compared to standard medical therapy?
Population
90 prospective S/V patients and 90 retrospective control patients with HFrEF
Comparison
Sacubitril/Valsartan vs standard medical therapy
Design
Prospective observational cohort compared with a retrospective cohort
Follow-up
12 months
Authors
Loading...
S/V was associated with reduced cardiac death/HF rehospitalization in real-world HFrEF; leaves open whether benefits are causal.
Does Sacubitril/Valsartan reduce the composite of cardiac death and HF rehospitalization in patients with HFrEF compared to standard medical therapy?
In a real-world HFrEF population, sacubitril/valsartan significantly reduced the 1-year risk of cardiac death and heart failure rehospitalization while improving echocardiographic parameters compared to standard medical therapy.
Polito et al. (2020) studied this question.